AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15377554 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 1676
Study 12187039 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 115
Study 12187039 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 115
Study 9846847 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleate meal (95 g fat)
Number of subjects: 12
Study 9846847 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (18 g MCT)
Number of subjects: 12
Study 7865062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (2 x ED 95)
Number of subjects: 30
Study 7865062 — intervention group
Group type: COMPARATOR
Intervention: 0.06 mg/kg rocuronium as priming dose followed by 0.24 mg/kg intubating dose
Number of subjects: 30
Study 7865062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (0.6 mg/kg and 0.06 mg/kg + 0.24 mg/kg)
Number of subjects: 30
Study 2690557 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant single-agent doxorubicin
Number of subjects: 240
Study 2690557 — intervention group
Group type: EXPERIMENTAL
Intervention: No or one risk factor
Number of subjects: 240
Study 2690557 — intervention group
Group type: EXPERIMENTAL
Intervention: Two risk factors
Number of subjects: 240
Study 2690557 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or four risk factors
Number of subjects: 240
Study 1060744 — intervention group
Group type: EXPERIMENTAL
Intervention: POMP alone
Number of subjects: 24
Study 1060744 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAVD
Number of subjects: 24
Study 1060744 — intervention group
Group type: EXPERIMENTAL
Intervention: POMP-PRAVD
Number of subjects: 24
Study 1060744 — intervention group
Group type: EXPERIMENTAL
Intervention: POMP
Number of subjects: 24
Study 1060744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients less than 16 years
Number of subjects: 24
Study 1060744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients greater than 16 years
Number of subjects: 24
Study 31561014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic diagnostic accuracy studies
Number of subjects: 0
Study 31561014 — intervention group
Group type: COMPARATOR
Intervention: Explanatory diagnostic accuracy studies
Number of subjects: 0
Study 30637662 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg/day selenium supplements as selenium yeast (n=17)
Number of subjects: 33
Study 29774682 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol/Melitracen 10.5 mg, QD, treatment lasts 4 months
Number of subjects: 99
Study 29774682 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific immunotherapy only)
Number of subjects: 99
Study 29774682 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol/Melitracen combined with specific immunotherapy
Number of subjects: 99
Study 25917673 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent OPV (bOPV) + inactivated polio vaccine (IPV)
Number of subjects: 928
Study 25917673 — intervention group
Group type: COMPARATOR
Intervention: bivalent OPV (bOPV) only
Number of subjects: 928
Study 23452344 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) using high-dose rocuronium, reversed by 4 mg/kg sugammadex
Number of subjects: 24
Study 23452344 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (NMB) using a combination of atracurium and mivacurium, reversed by 1 mg neostigmine and 0.5 mg atropine
Number of subjects: 24
Study 21239052 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention package delivered by lady health workers (LHWs) including promotion of antenatal care, maternal health education, clean delivery kits, facility births, immediate newborn care, identification of danger signs, and promotion of care-seeking.
Number of subjects: 12391
Study 21239052 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention package delivered by lady health workers (LHWs).
Number of subjects: 12391
Study 21239052 — intervention group
Group type: COMPARATOR
Intervention: Routine care provided in control clusters.
Number of subjects: 12391
Study 19483447 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 50
Study 19483447 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy
Number of subjects: 50
Study 17914039 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day
Number of subjects: 272
Study 17914039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 15472765 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 159
Study 15472765 — intervention group
Group type: COMPARATOR
Intervention: Girdlestone situation (Control)
Number of subjects: 159
Study 11510790 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CPAP therapy
Number of subjects: 33
Study 11510790 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto CPAP therapy
Number of subjects: 33
Study 9660042 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 4 microg/kg
Number of subjects: 40
Study 9660042 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam 0.2 mg/kg
Number of subjects: 40
Study 7646097 — intervention group
Group type: EXPERIMENTAL
Intervention: Completely heparin-coated circuit with reduced heparin dose (activated clotting time > 250 seconds)
Number of subjects: 203
Study 7646097 — intervention group
Group type: COMPARATOR
Intervention: Control group with uncoated circuit and full systemic heparinization (activated clotting time > 480 seconds)
Number of subjects: 203
Study 7646097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 203
Study 2785402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position using a newly designed obstetric chair
Number of subjects: 304
Study 2785402 — intervention group
Group type: COMPARATOR
Intervention: Conventional dorsal position
Number of subjects: 304
Study 23704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 183
Study 23704 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 183
Study 23704 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 183
Study 31809394 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous iliac bone graft
Number of subjects: 135
Study 31809394 — intervention group
Group type: COMPARATOR
Intervention: Bioresorbable hydroxyapatite and calcium sulfate cement (CBVF)
Number of subjects: 135
Study 31365402 — intervention group
Group type: EXPERIMENTAL
Intervention: Female MD
Number of subjects: 160
Study 31365402 — intervention group
Group type: EXPERIMENTAL
Intervention: Male MD
Number of subjects: 160
Study 31365402 — intervention group
Group type: EXPERIMENTAL
Intervention: Female NP
Number of subjects: 160
Study 31365402 — intervention group
Group type: EXPERIMENTAL
Intervention: Male NP
Number of subjects: 160
Study 28599901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercurrent cardiovascular events (CV events)
Number of subjects: 4022
Study 28599901 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 4022
Study 28599901 — intervention group
Group type: COMPARATOR
Intervention: Myocardial infarction or stroke
Number of subjects: 4022
Study 28599901 — intervention group
Group type: COMPARATOR
Intervention: Pre-ESRD events
Number of subjects: 4022
Study 28599901 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ESRD mortality
Number of subjects: 4022
Study 25484354 — intervention group
Group type: EXPERIMENTAL
Intervention: normobaric hypoxic bed rest (HBR)
Number of subjects: 11
Study 25484354 — intervention group
Group type: EXPERIMENTAL
Intervention: normobaric hypoxic ambulatory confinement (HAMB)
Number of subjects: 11
Study 25484354 — intervention group
Group type: COMPARATOR
Intervention: normobaric normoxic bed rest (NBR)
Number of subjects: 11
Study 23459906 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving Heart Program (intervention)
Number of subjects: 136
Study 23459906 — intervention group
Group type: COMPARATOR
Intervention: Standard-care control group
Number of subjects: 136
Study 21164384 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 1150
Study 19582982 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PHQ-12 item questionnaire
Number of subjects: 100
Study 19582982 — intervention group
Group type: COMPARATOR
Intervention: PHQ-9 item questionnaire
Number of subjects: 100
Study 16499978 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial screening procedures for inclusion and exclusion criteria
Number of subjects: 0
Study 16499978 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected women
Number of subjects: 0
Study 15169793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m²
Number of subjects: 474
Study 15169793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 210 mg/m²
Number of subjects: 474
Study 15169793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m²
Number of subjects: 474
Study 15169793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (all doses)
Number of subjects: 474
Study 15169793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (higher doses)
Number of subjects: 474
Study 15176518 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 60
Study 15176518 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study 10671187 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (3 times a week for 12 weeks)
Number of subjects: 29
Study 9387047 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomally encapsulated daunorubicin (DaunoXome) at 120 mg/m2 repeated every 21 days
Number of subjects: 19
Study 9387047 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomally encapsulated daunorubicin (DaunoXome) at 40 mg/m2 repeated every 14 days
Number of subjects: 19
Study 8404181 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt loading (+ 6.1 +/‐ 2.8 g NaCl/d = + 105 +/‐ 48 mmol Na)
Number of subjects: 14
Study 8404181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate loading (+ 140 +/‐ 40 ml Shohl's solution, = + 120 +/‐ 30 mmol Na)
Number of subjects: 14
Study 8404181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (5 to 6 g NaCl/d = 86 to 103 mmol Na)
Number of subjects: 14
Study 3528541 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg disulfiram
Number of subjects: 605
Study 3528541 — intervention group
Group type: COMPARATOR
Intervention: 1 mg disulfiram
Number of subjects: 605
Study 3528541 — intervention group
Group type: COMPARATOR
Intervention: No disulfiram
Number of subjects: 605
Study 2645950 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated treatment with daunorubicin (DNR), vincristine (VCR), and cytosine arabinoside (ara‐C)
Number of subjects: 515
Study 2645950 — intervention group
Group type: COMPARATOR
Intervention: Alternating treatment with amsacrine (AMSA) combined with high dose ara‐C and 5-azacytidine
Number of subjects: 515
Study 2645950 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 515
Study 2645950 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for patients achieving CR
Number of subjects: 515
Study 2645950 — intervention group
Group type: COMPARATOR
Intervention: Intensive combination of high-dose ara‐C and AMSA
Number of subjects: 515
Study 31186180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-assisted reconstruction
Number of subjects: 60
Study 31186180 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-free reconstruction
Number of subjects: 60
Study 27337738 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-exergaming (iPACES)
Number of subjects: 30
Study 27337738 — intervention group
Group type: COMPARATOR
Intervention: Exergaming alone
Number of subjects: 30
Study 27337738 — intervention group
Group type: COMPARATOR
Intervention: Neurogaming alone
Number of subjects: 30
Study 25599904 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPA-enhanced mindfulness training
Number of subjects: 321
Study 25599904 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic mindfulness training
Number of subjects: 321
Study 25599904 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 321
Study 23404591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 75
Study 23404591 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 75
Study 21054754 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of udenafil given 1 h before TURP
Number of subjects: 30
Study 21054754 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil given 1 h before TURP
Number of subjects: 30
Study 21054754 — intervention group
Group type: COMPARATOR
Intervention: TURP without PDE5 Is
Number of subjects: 30
Study 19145785 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care based on teletransmitted home blood pressure (group B, n = 216)
Number of subjects: 329
Study 19145785 — intervention group
Group type: COMPARATOR
Intervention: Usual care based on office blood pressure (group A, n = 113)
Number of subjects: 329
Study 17729044 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-awareness training during IADLs (6 sessions)
Number of subjects: 20
Study 17729044 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic practice during IADLs
Number of subjects: 20
Study 15553286 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental technique with steel matrix bands
Number of subjects: 88
Study 15553286 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental technique with polyester matrix bands
Number of subjects: 88
Study 15553286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepolymerized resin particles with steel matrix bands
Number of subjects: 88
Study 15553286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepolymerized resin particles with polyester matrix bands
Number of subjects: 88
Study 11465985 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adenosine infusion (50 microg/kg/min for 60 min)
Number of subjects: 26
Study 11465985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11465985 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adenosine infusion
Number of subjects: 26
Study 9729704 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 54
Study 8276659 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, 450 mg/m2 intravenously for 3 consecutive days during the first and last weeks of radiation therapy; Levamisole, 50 mg orally 3 times daily for 3 consecutive days concurrent with radiation therapy and 5-fluorouracil.
Number of subjects: 15
Study 2606855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NIC)
Number of subjects: 7
Study 2606855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 7
Study 4844514 — intervention group
Group type: EXPERIMENTAL
Intervention: Quingestanol acetate (1.5 mg postcoital)
Number of subjects: 899
Study 4844514 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐norgestrel (3.35 mg postcoital)
Number of subjects: 899
Study 30649238 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (3 cycles of 5-min ischaemia/5-min reperfusion of the right arm using a blood pressure cuff inflated to 200 mmHg)
Number of subjects: 134
Study 30649238 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 134
Study 30649238 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 134
Study 30649238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 25984590 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Streaming (ES)
Number of subjects: 35
Study 25984590 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Consultation (PC)
Number of subjects: 35
Study 25984590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact Sheet Self-Study (FS)
Number of subjects: 35
Study 25984590 — intervention group
Group type: COMPARATOR
Intervention: All support programs (ES, PC, FS)
Number of subjects: 35
Study 24888428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (rt-PA) for anterior circulation strokes in patients with LVO
Number of subjects: 225
Study 24888428 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis (rt-PA) for anterior circulation strokes in patients with No-LVO
Number of subjects: 225
Study 23271170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 23271170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21691117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (20 mg/kg/day for 3 weeks)
Number of subjects: 40
Study 19877264 — intervention group
Group type: EXPERIMENTAL
Intervention: TMG+
Number of subjects: 93
Study 19877264 — intervention group
Group type: COMPARATOR
Intervention: TMG-
Number of subjects: 93
Study 16952727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular anesthesia
Number of subjects: 107
Study 16952727 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 107
Study 15499485 — intervention group
Group type: COMPARATOR
Intervention: Preventive Orientation (PO)
Number of subjects: 99
Study 15499485 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 99
Study 15499485 — intervention group
Group type: COMPARATOR
Intervention: Control group of non-users in the last month (CONUM)
Number of subjects: 99
Study 15499485 — intervention group
Group type: COMPARATOR
Intervention: Control group of users in the last month (COUM)
Number of subjects: 99
Study 11561207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention programme for allergy
Number of subjects: 43
Study 11561207 — intervention group
Group type: COMPARATOR
Intervention: Control group recommendations
Number of subjects: 43
Study 11561207 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaire
Number of subjects: 43
Study 11561207 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 43
Study 11561207 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of specific IgE against house-dust mite
Number of subjects: 43
Study 9482363 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, aspirin, and caffeine combination
Number of subjects: 1250
Study 9482363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study 7923517 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium administered to patients with HPT
Number of subjects: 20
Study 7923517 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium administered to control patients
Number of subjects: 20
Study 2894904 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg b.i.d.)
Number of subjects: 23
Study 2894904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31830868 — intervention group
Group type: EXPERIMENTAL
Intervention: arts therapies intervention
Number of subjects: 64
Study 30925012 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational film about body donors
Number of subjects: 77
Study 27273298 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bovine bone mineral with 10% collagen (DBBM‐C) grafting
Number of subjects: 86
Study 27273298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no grafting)
Number of subjects: 86
Study 26305528 — intervention group
Group type: EXPERIMENTAL
Intervention: First-eye cataract surgery
Number of subjects: 101
Study 26305528 — intervention group
Group type: COMPARATOR
Intervention: Second-eye cataract patients
Number of subjects: 101
Study 26305528 — intervention group
Group type: COMPARATOR
Intervention: Second-eye patients
Number of subjects: 101
Study 24884624 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS
Number of subjects: 60
Study 24884624 — intervention group
Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 60
Study 24884624 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 60
Study 24884624 — intervention group
Group type: EXPERIMENTAL
Intervention: Single brain site involvement
Number of subjects: 60
Study 24884624 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lesion
Number of subjects: 60
Study 22920307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (75 mg of clopidogrel in addition to 300 mg of aspirin)
Number of subjects: 0
Study 22920307 — intervention group
Group type: COMPARATOR
Intervention: Control group (300 mg of aspirin)
Number of subjects: 0
Study 19702702 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) 0.05% ophthalmic emulsion twice daily and concomitant five times daily non-preserved artificial tear
Number of subjects: 64
Study 19702702 — intervention group
Group type: COMPARATOR
Intervention: Vehicle emulsion twice daily and non-preserved artificial tear five times daily (Control)
Number of subjects: 64
Study 19702702 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA)
Number of subjects: 64
Study 17688611 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN‐SR 60 mg vaginally
Number of subjects: 156
Study 17688611 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C 100 mg vaginally
Number of subjects: 156
Study 15173774 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation-corrected MPI with ECG-gated data
Number of subjects: 90
Study 15173774 — intervention group
Group type: COMPARATOR
Intervention: MPI alone
Number of subjects: 90
Study 15173774 — intervention group
Group type: COMPARATOR
Intervention: MPI plus ECG-gated data
Number of subjects: 90
Study 11172267 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave polyethylene insert (C, n = 25)
Number of subjects: 43
Study 11172267 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized polyethylene insert (PS, n = 22)
Number of subjects: 43
Study 9556010 — intervention group
Group type: EXPERIMENTAL
Intervention: Human surfactant given at birth (prophylactic)
Number of subjects: 40
Study 9556010 — intervention group
Group type: EXPERIMENTAL
Intervention: Human surfactant given after development of neonatal respiratory distress syndrome (rescue)
Number of subjects: 40